Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: A Dutch multicenter phase II study

British Journal of Cancer

Volumn 94, Issue 5, 2006, Pages 625-630

  Baas, P ^a   Belderbos, J S A ^a   Senan, S ^b,e   Kwa, H B ^c   Van Bochove, A ^d   Van Tinteren, H ^a   Burgers, J A ^a,b   Van Meerbeeck, J P ^b,f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Rotterdam Oncological Thoracic Study Group ROTS   (Netherlands)

^c Onze Lieve Vrouwen Gasthuis ^*  (Netherlands)

^d ZAANS MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GHENT UNIVERSITY   (Belgium)

Author keywords

Concurrent radiotherapy; Involved field; Limited stage; SCLC

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CLEMASTINE; DEXAMETHASONE; ETOPOSIDE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DYSPNEA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPONATREMIA; INFECTION; LETHARGY; LUNG SMALL CELL CANCER; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NETHERLANDS; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION PNEUMONIA; SKULL IRRADIATION; SURVIVAL RATE; SURVIVAL TIME; THORAX; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RADIATION INJURIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644840888     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602979     Document Type: Article

References (34)

1. Bunn Jr PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livinston R, Weiss GR, Hicks WJ, Gandara DR (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13(7): 1632-1641
2. Bunn PA, Greco FA, Einhorn L (1986) Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in limited small cell lung cancer. Semin Oncol 13(3 Suppl 3): S45-S53
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11): 1748-1756
4. Choy H, Devore III RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Centre Affiliate Network Study). Int J Radiat Oncol Biol Phys 47(4): 931-937
5. EORTC. Phase II trials in the EORTC (1997) The Protocol Review Committee, the Data Centre, the Research and Treatment Division, and the New Drug Development Office. European Organization for Research and Treatment of Cancer. Eur J Cancer 33(9): 1361-1363
6. Erridge SC, Murray N (2003) Thoracic radiotherapy for limited-stage small cell lung cancer: issues of timing, volumes, dose, and fractionation. Semin Oncol 30(1): 26-37
7. Ettinger DS (2001) New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 28(2 Suppl 4): 27-29
8. Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran Jr WJ, Movsas B, Byhardt RW, Radiation Therapy Oncology Group 9609 (2005) Study of Paclitaxel, Etoposide, and Cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with Limited Stage Small Cell Lung Cancer: a Radiation Therapy Oncology Group 9609 Phase II study. J Clin Oncol 23: 4991-4998
9. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13(6): 1430-1435
10. Friedman MA, Bozdech MJ, Billingham ME, Rider AK (1978) Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 240(15): 1603-1606
11. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, Vendrik C, Roozendaal K, Planting AS, Quoix E, for the EORTC (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11(7): 1230-1240
12. Green M, Seal KHL (1990) Carboplatin in non small cell lung cancer: The Cancer and Leukemia Group B experience. Carboplatin (JM-8) Current perspectives and future directions. Philadelphia: WB Saunders Company, pp 301-306
13. Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA (1997) Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 15(12): 3464-3470
14. Hainsworth JD, Greco FA (1995) Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy. Semin Oncol 22(6 Suppl 15): 45-49
15. Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS (2005) Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 23(15): 3488-3494
16. Johnson BE, Grayson J, Makuch RW, Linnoila RI, Anderson MJ, Cohen MH, Gladstein E, Minna JD, Ihde DC (1990) Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 8(3): 396-401
17. Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H (1997) A phase I/ II study of paclitaxel (PACLITAXEL) and concurrent radiotherapy in advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 39(5): 1107-1111
18. Kirschling RJ, Grill JP, Marks RS, Kugler JW, Gerstner JB, Kuross SA, Michalak JC, Windschitl HE, Krewer KD, Jett JR (1999) Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 22(5): 517-522
19. Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W (1997) Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Centre study 94-001. Semin Oncol 24(4 Suppl 12): S12
20. Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK (2004) Practice guideline for the combination chemotherapy in the initial management of limited stage small-cell lung cancer. Lung Cancer 43: 223-240
21. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, Evans WK, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun JA, Wilson K, for the National Cancer Institute of Canada Clinical trials Group (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11(2): 336-344
22. Neill HB, Herndon II JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green M (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23(16): 3752-3759
23. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, for the Japanes Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2): 85-91
24. Payne DG, Murray N, Warde P (1994) Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy. Bull Cancer 81(2): 119-128
25. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Østerlind K, Martin HN, Tattersall HN, Wagner H (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327(23): 1618-1624
26. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouvas G, Theocharis D, Panousaka E, Boleti E, Sphakianoudis G, Pavlidis N (1994) Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5(7): 601-607
27. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20(14): 3054-3060
28. Thomas P, Castelnau O, Paillotin H, Robinet LG, Muir JF, Delaval P, Gouva S, Balmes P, Blanchon F, Perdu D, Poirier R, Pommier De Santi P, Penot-Ragon C, Kleisbauer JP (2001) Phase II trial of Paclitaxel and Carboplatin in metastatic Small-Cell Lung Cancer: A Groupe Francais de Pneumo-Cancerologie Study. J Clin Oncol 19: 1320-1325
29. Thomas P, Kleisbauer JP, Robinet G, Clavier J, Poirier R, Vernenegre A, Bonnaud F, Taytard A, Paillotin D, Pommier De Santi P, Barriere JR (1997) Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy. A phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.). Lung Cancer 18(1): 71-81
30. Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown Jr BW, Hannigan Jr JF, Meyers FJ, Mitchell EP, Billingham ME (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46(7): 3722-3727
31. Turrisi (1998) Observations after 5 year follow-up of Intergroup trial 0096: 4 cycles of cisplatin and etoposide and concurrent 45 Gy thoracic radiotherapy given in daily (QD) or twice daily fractions followed by 25 Gy PCI. Survival differences and patterns of failure. pASCO abstract 1757
32. Turrisi III AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340(4): 265-271
33. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10(6): 890-895
34. Wu HG, Choy H (2002) Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer. (Review). Oncology 16(Suppl 9): 13-18